

Protocol Title: A Cross-over study comparing the bioavailability Phytofare™ against Phytofare™ Pheroid® Catechin Complex and a generic green tea extract

Protocol Number: Plandai-2013-001

Sponsor: Plandai Biotechnology, Inc.

3 September 2014

PLANDAI BIOTECHNOLOGY INC. BIOAVAILABILITY TRIAL PRELIMINARY RESULTS

A human phase one bioavailability trial approved by the North West University, Potchefstroom campus, South African Human Research Ethics Committee (HREC nr: NWU-00004-14-A1) and monitored for GCP compliance by Logic Trials Clinical Research (Pty) Ltd, compared a green tea complex prepared by Phytofare™ technology with a commercial green tea extract (comparator).

Findings

1. Phytofare™ raw material has double the amount of total catechins per mass than the tested comparator.
2. When comparing the commercial green tea with Phytofare™ technology the results showed a ten fold increase of eight catechins in the blood. The comparator resulted in only two detectable catechins from comparator.
3. Absorption of catechins were enhanced five times when using Phytofare™ technology as compared to the commercial green tea complex.
4. In comparison with the commercial complex, the life span of the catechins molecules in the blood were doubled in the case of the Phytofare™. The bioavailability was therefore increased ten times for the eight catechins recognised including EGCG.

Further investigation

A common problem of all commercial green tea catechin extracts including Phytofare™, is shelf life. Catechins produced by Phytofare™ technology will be entrapped in Pheroid® in an attempt to improve shelf life.

Prof Anne Grobler

Director : DST / NWU Preclinical Drug Development Platform

Liezl-Marie Scholtz

Quality Assurance Manager: DST / NWU Preclinical Drug Development Platform
